On the need to compensate for edema-induced dose reductions in preplanned 131Cs prostate brachytherapy

被引:12
作者
Chen, Z. Jay [1 ]
Deng, Jun [1 ]
Roberts, Kenneth [1 ]
Nath, Ravinder [1 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 70卷 / 01期
关键词
prostate edema; prostate brachytherapy; edema-induced dose reduction; Cs-131; I-125;
D O I
10.1016/j.ijrobp.2007.09.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Surgical trauma-induced edema and its protracted resolution can lead to significant dose reductions in preplanned Cs-131 prostate brachytherapy. The purpose of this work was to examine whether these dose reductions should be actively compensated for and to estimate the magnitude of the additional irradiation needed for dose compensation. Methods and Materials: The quantitative edema resolution characteristics observed by Waterman et A were used to examine the physical and radiobiologic effects of prostate edema in preplanned Cs-131 implants. The need for dose compensation was assessed using the dose responses observed in I-125 and Pd-103 prostate implants. The biologically effective dose, calculated with full consideration of edema evolution, was used to estimate the additional irradiation needed for dose compensation. Results: We found that the edema-induced dose reduction in preplanned Cs-131 implants could easily exceed 10% of the prescription dose for implants with moderate or large edema. These dose reductions could lead to a >10% reduction in the biochemical recurrence-free survival for individual patients if the effect of edema was ignored. For a prescribed dose of 120 Gy, the number of 2-Gy external beam fractions needed to compensate for a 5%, 10%, 15%, 20%, and 25% edema-induced dose reduction would be one, four, six, seven, and nine, respectively, for prostate cancer with a median potential doubling time of 42 days. The required additional irradiation increased for fast-growing tumors and/or those less efficient in sublethal damage repair. Conclusion: Compensation of edema-induced dose reductions in preplanned Cs-131 prostate brachytherapy should be actively considered for those implants with moderate or large edema. (C) 2008 Elsevier Inc.
引用
收藏
页码:303 / 310
页数:8
相关论文
共 45 条
[31]   A MODIFIED TECHNIQUE ALLOWING INTERACTIVE ULTRASOUND-GUIDED 3-DIMENSIONAL TRANSPERINEAL PROSTATE IMPLANTATION [J].
STOCK, RG ;
STONE, NN ;
WESSON, MF ;
DEWYNGAERT, JK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (01) :219-225
[32]   A dose-response study for I-125 prostate implants [J].
Stock, RG ;
Stone, NN ;
Tabert, A ;
Iannuzzi, C ;
DeWyngaert, JK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (01) :101-108
[33]  
Stone Nelson N, 2003, Brachytherapy, V2, P17, DOI 10.1016/S1538-4721(03)00005-9
[34]   TIME-DOSE FACTORS IN RADIOTHERAPY - A REVIEW OF THE HUMAN DATA [J].
THAMES, HD ;
BENTZEN, SM ;
TURESSON, I ;
OVERGAARD, M ;
VANDENBOGAERT, W .
RADIOTHERAPY AND ONCOLOGY, 1990, 19 (03) :219-235
[35]   The low α/β ratio for prostate cancer:: What does the clinical outcome of HDR brachytherapy tell [J].
Wang, JZ ;
Li, XA ;
Yu, CX ;
DiBiase, SJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (04) :1101-1108
[36]   How low is the α/β ratio for prostate cancer? [J].
Wang, JZ ;
Guerrero, M ;
Li, XA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (01) :194-203
[37]   Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition [J].
Waterman, FM ;
Yue, N ;
Corn, BW ;
Dicker, AP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05) :1069-1077
[38]   Dosimetric comparison of pre-planned and OR-planned prostate seed brachytherapy [J].
Wilkinson, DA ;
Lee, EJ ;
Ciezki, JP ;
Mohan, D ;
Zippe, C ;
Angermeier, K ;
Ulchaker, J ;
Klein, EA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (04) :1241-1244
[39]  
Willins J, 1998, Radiat Oncol Investig, V6, P157, DOI 10.1002/(SICI)1520-6823(1998)6:4<157::AID-ROI2>3.0.CO
[40]  
2-X